IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study

The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19). In this study, COVID-19 ARDS patients admitted to the Azienda Socio Sanitaria Territoriale of Lecco, Italy, between March 5th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunol
Autores principales: Franzetti, Marco, Forastieri, Andrea, Borsa, Noemi, Pandolfo, Alessandro, Molteni, Chiara, Borghesi, Luca, Pontiggia, Silvia, Evasi, Giulia, Guiotto, Lorenzo, Erba, Mattia, Pozzetti, Ugo, Ronchetti, Anna, Valsecchi, Letizia, Castaldo, Gioacchino, Longoni, Ernesto, Colombo, Daniele, Soncini, Marco, Crespi, Stefano, Maggiolini, Stefano, Guzzon, Davide, Piconi, Stefania
Formato: Artigo
Lenguaje:Inglês
Publicado: AAI 2021
Materias:
Infectious Disease and Host Response
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7980530/
https://ncbi.nlm.nih.gov/pubmed/33547169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.2001126
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares